SREBP1 Antibody | Affinity Biosciences

Product:	SREBP1 Antibody
Catalog:	AF6283
Description:	Rabbit polyclonal antibody to SREBP1
Application:	WB IHC IF/ICC
Cited expt.:	WB, IHC, IF/ICC
Reactivity:	Human, Mouse, Rat, Pig, Sheep
Prediction:	Pig, Horse, Sheep, Dog
Mol.Wt.:	122kD, 65kD(cleaved); 122kD(Calculated).
Uniprot:	P36956
RRID:	AB_2835134

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat,Pig,Sheep

Prediction:

Horse(100%), Dog(100%)

Clonality:

Polyclonal

Specificity:

SREBP1 Antibody detects endogenous levels of total SREBP1.

RRID:

AB_2835134
Cite Format: Affinity Biosciences Cat# AF6283, RRID:AB_2835134.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

ADD 1; bHLHd1; Class D basic helix-loop-helix protein 1; D630008H06; Processed sterol regulatory element-binding protein 1; SRBP1_HUMAN; SREBF 1; SREBF1; SREBP 1; SREBP 1c; SREBP-1; SREBP1; Sterol regulatory element binding protein 1; Sterol Regulatory Element Binding Transcription Factor 1 / Protein 1; Sterol regulatory element binding transcription factor 1; Sterol regulatory element-binding transcription factor 1;

Immunogens

Immunogen:

A synthesized peptide derived from human SREBP1, corresponding to a region within the internal amino acids.

Uniprot:

P36956(SRBP1_HUMAN) >>Visit HPA database.

Gene(ID):

SREBF1(6720)

Expression:

P36956 SRBP1_HUMAN:

Expressed in a wide variety of tissues, most abundant in liver and adrenal gland. In fetal tissues lung and liver shows highest expression. Isoform SREBP-1C predominates in liver, adrenal gland and ovary, whereas isoform SREBP-1A predominates in hepatoma cell lines. Isoform SREBP-1A and isoform SREBP-1C are found in kidney, brain, white fat, and muscle.

Description:

This gene encodes a transcription factor that binds to the sterol regulatory element-1 (SRE1), which is a decamer flanking the low density lipoprotein receptor gene and some genes involved in sterol biosynthesis. The protein is synthesized as a precursor that is attached to the nuclear membrane and endoplasmic reticulum.

Sequence:

P36956 SRBP1_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MDEPPFSEAALEQALGEPCDLDAALLTDIEDMLQLINNQDSDFPGLFDPPYAGSGAGGTDPASPDTSSPGSLSPPPATLSSSLEAFLSGPQAAPSPLSPPQPAPTPLKMYPSMPAFSPGPGIKEESVPLSILQTPTPQPLPGALLPQSFPAPAPPQFSSTPVLGYPSPPGGFSTGSPPGNTQQPLPGLPLASPPGVPPVSLHTQVQSVVPQQLLTVTAAPTAAPVTTTVTSQIQQVPVLLQPHFIKADSLLLTAMKTDGATVKAAGLSPLVSGTTVQTGPLPTLVSGGTILATVPLVVDAEKLPINRLAAGSKAPASAQSRGEKRTAHNAIEKRYRSSINDKIIELKDLVVGTEAKLNKSAVLRKAIDYIRFLQHSNQKLKQENLSLRTAVHKSKSLKDLVSACGSGGNTDVLMEGVKTEVEDTLTPPPSDAGSPFQSSPLSLGSRGSGSGGSGSDSEPDSPVFEDSKAKPEQRPSLHSRGMLDRSRLALCTLVFLCLSCNPLASLLGARGLPSPSDTTSVYHSPGRNVLGTESRDGPGWAQWLLPPVVWLLNGLLVLVSLVLLFVYGEPVTRPHSGPAVYFWRHRKQADLDLARGDFAQAAQQLWLALRALGRPLPTSHLDLACSLLWNLIRHLLQRLWVGRWLAGRAGGLQQDCALRVDASASARDAALVYHKLHQLHTMGKHTGGHLTATNLALSALNLAECAGDAVSVATLAEIYVAAALRVKTSLPRALHFLTRFFLSSARQACLAQSGSVPPAMQWLCHPVGHRFFVDGDWSVLSTPWESLYSLAGNPVDPLAQVTQLFREHLLERALNCVTQPNPSPGSADGDKEFSDALGYLQLLNSCSDAAGAPAYSFSISSSMATTTGVDPVAKWWASLTAVVIHWLRRDEEAAERLCPLVEHLPRVLQESERPLPRAALHSFKAARALLGCAKAESGPASLTICEKASGYLQDSLATTPASSSIDKAVQLFLCDLLLVVRTSLWRQQQPPAPAPAAQGTSSRPQASALELRGFQRDLSSLRRLAQSFRPAMRRVFLHEATARLMAGASPTRTHQLLDRSLRRRAGPGGKGGAVAELEPRPTRREHAEALLLASCYLPPGFLSAPGQRVGMLAEAARTLEKLGDRRLLHDCQQMLMRLGGGTTVTSS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Pig

100

Horse

100

Sheep

100

Dog

100

Bovine

Xenopus

Zebrafish

Chicken

Rabbit

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

P36956_SRBP1_HUMAN

Function:

Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the fatty acid and to a lesser degree the cholesterol synthesis pathway (By similarity). Binds to the sterol regulatory element 1 (SRE-1) (5'-ATCACCCCAC-3'). Has dual sequence specificity binding to both an E-box motif (5'-ATCACGTGA-3') and to SRE-1 (5'-ATCACCCCAC-3').

PTMs:

At low cholesterol the SCAP/SREBP complex is recruited into COPII vesicles for export from the ER. In the Golgi complex SREBPs are cleaved sequentially by site-1 and site-2 protease. The first cleavage by site-1 protease occurs within the luminal loop, the second cleavage by site-2 protease occurs within the first transmembrane domain and releases the transcription factor from the Golgi membrane. Apoptosis triggers cleavage by the cysteine proteases caspase-3 and caspase-7.

Phosphorylated by AMPK, leading to suppress protein processing and nuclear translocation, and repress target gene expression. Phosphorylation at Ser-402 by SIK1 represses activity possibly by inhibiting DNA-binding (By similarity).

Subcellular Location:

Endoplasmic reticulum membrane>Multi-pass membrane protein. Golgi apparatus membrane>Multi-pass membrane protein. Cytoplasmic vesicle>COPII-coated vesicle membrane>Multi-pass membrane protein.
Note: Moves from the endoplasmic reticulum to the Golgi in the absence of sterols.

Nucleus.

Nucleus.

Nucleus.

Tissue Specificity:

Family&Domains:

The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Belongs to the SREBP family.

Research Fields

· Environmental Information Processing > Signal transduction > AMPK signaling pathway. (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Organismal Systems > Endocrine system > Insulin signaling pathway. (View pathway)

References

1). Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism. Cell metabolism, 2023 (PubMed: 33186558) [IF=27.7]

2). Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 (PubMed: 39976110) [IF=15.1]

Application: WB Species: human Sample: HSP90 of HepG2 cells

Figure 5 Effects of B6 on de novo lipogenesis and fatty acid oxidation in AML12 cells. A,B) Oil Red O staining and optical density of AML12 cells treated with B6 of different concentration for 24 h. The experiment was conducted independently on four occasions. C) Protein expression of HDAC11, SREBP1c, FASN, SCD1, and HSP90 of HepG2 cells treated with FFA and 0.5 × 10−6 m B6 for 24 h (n = 3 biological replicates). D–F) Relative normalized mRNA expression of SREBP1c, FASN, and SCD1 of indicated cells (n = 4 biological replicates). mRNA level of β-actin was used as normalized control. G) Mito-Tracker Deep Red FM staining of indicated cells. The experiment was conducted independently on three occasions. H) Mitochondrial oxygen consumption rate in indicated cells (n = 3 biological replicates). I) Protein expression of CPT1A, PGC1α, PPARα, and HSP90 in indicated cells (n = 3 biological replicates). J–L) Relative normalized mRNA expression of CPT1A, PGC1α, and PPARα of indicated cells (n = 4 biological replicates). mRNA level of β-actin was used as normalized control. Data are shown as mean ± SD. The p-values were calculated by one-way ANOVAs.

3). Hyperimonates A and B, a pair of unprecedented polyprenylated acylphloroglucinols from Hypericum monogynum: Structural elucidation, total synthesis, and lipid-lowering activity. Acta pharmaceutica Sinica. B, 2026 (PubMed: 41685146) [IF=14.7]

Application: WB Species: human Sample: HepG2 cells

Figure 4. Effect of compound 1 on the expression levels of proteins in OA/Fro-induced HepG2 cells. (A, G) The expression levels of proteins were analyzed by Western blot in OA/Fro-induced HepG2 cells after treatment with compound 1 for 48 h. (B–F, H–M) Schematic diagram showing the mechanism of the protective effect of compound 1 on lipid metabolism disorder. Results are expressed as the mean ± SD (n = 3). #P < 0.05, ##P < 0.01 and ###P < 0.001 compared with the control group; ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 compared with the model group.

4). Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1. Acta pharmaceutica Sinica. B, 2025 (PubMed: 40698135) [IF=14.7]

Application: WB Species: Mouse Sample:

Figure 2. SF exacerbated lipid metabolism disorders in mice. (A) KO annotation for the DEGs in testis between DM-SF vs. DM mice. (B) Effect of SF on characteristic genes indicative of lipid homeostasis and fatty acid metabolism pathway shown by GSEA analysis. (C) KEGG pathway enrichment analysis of DEGs in CSR rat (GSE141699). (D) GSEA analysis showed that CSR was negatively associated with fatty acid metabolism and fatty acid degradation. (E) KEGG pathway enrichment analysis of DEGs in timed sleep restriction mice (GSE38921). (F) A chordal graph of enriched KEGG terms showed the relationship between DEGs and KEGG pathways related to lipid metabolism. (G) TG and T-CHO content in serum and testis homogenates (n = 6). (H) SREBP1 and PPARA protein levels in the testis and densitometric quantification (n = 6). (I) Relative mRNA levels of Srebp1, Acaca, Fasn, Ppara, Acox1, Acadm, and Cpt1a in the testis (n = 6). Data shown in graphs represent the means ± SD; GAPDH was used as an internal control; ∗P < 0.05; NS, not significant.

5). CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease. Metabolism: clinical and experimental, 2024 (PubMed: 37952690) [IF=10.8]

6). Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation. Redox Biology, 2022 (PubMed: 35504134) [IF=10.7]

7). Fibroblast-derived POSTN promotes colorectal cancer progression under high-fat diet by reprogramming fatty acid metabolism in tumor cell. Cell communication and signaling : CCS, 2026 (PubMed: 41507973) [IF=8.4]

8). Celastrol-Loaded Targeted Antioxidative Nanozyme for Improving Lipid Metabolism and the Renal Microenvironment in Diabetic Nephropathy. ACS applied materials & interfaces, 2025 (PubMed: 40847274) [IF=8.3]

9). Anti-b diminishes hyperlipidaemia and hepatic steatosis in hamsters and mice by suppressing the mTOR/PPARγ and mTOR/SREBP1 signalling pathways. British journal of pharmacology, 2024 (PubMed: 39614407) [IF=7.3]

10). MED15 is upregulated by HIF-2α and promotes proliferation and metastasis in clear cell renal cell carcinoma via activation of SREBP-dependent fatty acid synthesis. Cell death discovery, 2024 (PubMed: 38649345) [IF=7.0]

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

SREBP1 Antibody - #AF6283